Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of small molecules that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 antagonist that is well-tolerated and effective against advanced cancers. The company is currently conducting Phase I/II and Phase II clinical programs in both solid and hematological malignancies with ONC201.

There are no current openings, please check back soon